Phathom Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
PHAT$5.45+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Deficit
(in thousands, except share amounts)
| Common Stock · Treasury Stock · AdditionalPaid-in · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Capital | Deficit | Deficit | |
| Balance at December 31, 2025 | 71,419,025 | $6 | 19 | $1,046,083 | $(1,484,258) | $(438,169) |
| 401(k) matching contribution | 132,035 | — | — | 2,074 | — | 2,074 |
| Vesting of restricted stock units and performance stock units, net of employee tax obligations | 740,564 | — | — | (128) | — | (128) |
| Stock-based compensation | — | — | — | 5,534 | — | 5,534 |
| ESPP shares issued | 211,837 | — | — | 1,538 | — | 1,538 |
| Issuance of common stock from exercises of stock options | 63,906 | — | — | 591 | — | 591 |
| Issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net | 6,875,000 | 1 | — | 121,973 | — | 121,974 |
| Net loss | — | — | — | — | (30,369) | (30,369) |
| Balance at March 31, 2026 | 79,442,367 | $7 | 19 | $1,177,665 | $(1,514,627) | $(336,955) |
| Common Stock · Treasury Stock · AdditionalPaid-in · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Capital | Deficit | Deficit | |
| Balance at December 31, 2024 | 68,518,238 | $6 | 19 | $1,009,425 | $(1,263,011) | $(253,580) |
| 401(k) matching contribution | 290,165 | — | — | 2,127 | — | 2,127 |
| Vesting of restricted stock units | 508,568 | — | — | — | — | — |
| Stock-based compensation | — | — | — | 5,540 | — | 5,540 |
| ESPP shares issued | 321,099 | — | — | 1,853 | — | 1,853 |
| Net loss | — | — | — | — | (94,316) | (94,316) |
| Balance at March 31, 2025 | 69,638,070 | $6 | 19 | $1,018,945 | $(1,357,327) | $(338,376) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.